An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity inPten+/−mice
Author(s) -
Katrina Podsypanina,
Richard Lee,
Chris Politis,
Ian Hennessy,
Allison Crane,
Janusz Puc,
Mehran S. Neshat,
Hong Wang,
Lin Yang,
Jay Gibbons,
Phil Frost,
Valley Dreisbach,
John Blenis,
Zbigniew Gaciong,
Peter Fisher,
Charles L. Sawyers,
Lora Hedrick-Ellenson,
Ramon Parsons
Publication year - 2001
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.171060098
Subject(s) - pten , p70 s6 kinase 1 , pi3k/akt/mtor pathway , protein kinase b , cancer research , rptor , kinase , microbiology and biotechnology , phosphorylation , signal transduction , chemistry , biology
PTEN phosphatase acts as a tumor suppressor by negatively regulating the phosphoinositide 3-kinase (PI3K) signaling pathway. It is unclear which downstream components of this pathway are necessary for oncogenic transformation. In this report we show that transformed cells of PTEN(+/-) mice have elevated levels of phosphorylated Akt and activated p70/S6 kinase associated with an increase in proliferation. Pharmacological inactivation of mTOR/RAFT/FRAP reduced neoplastic proliferation, tumor size, and p70/S6 kinase activity, but did not affect the status of Akt. These data suggest that p70/S6K and possibly other targets of mTOR contribute significantly to tumor development and that inhibition of these proteins may be therapeutic for cancer patients with deranged PI3K signaling.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom